Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
Useful Links
Refining diagnosis of multiple sclerosis with revised MRI criteria.
Immunosuppressive properties of mesenchymal stem cells: advances and applications.
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
One can prevent post-partum MS relapses by exclusive breast feeding: no.
Translating state-of-the-art spinal cord MRI techniques to clinical use: A systematic review of clinical studies utilizing DTI, MT, MWF, MRS, and fMRI.
Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis.
Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies.
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.
Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and RORγt responses and by increasing IL-10 production in experimental allergic encephalomyelitis.
Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells.
Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study.
The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
Interferon in relapsing-remitting multiple sclerosis.
Chemotactic Cytokines: Gordon Research Conference on Molecular and Cellular Mechanisms in Health and Disease
Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.
RTL therapy for multiple sclerosis: a Phase I clinical study.
Results of Phase III BRAVO Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment
Isolation of Clostridium perfringens Type B in an Individual at First Clinical Presentation of Multiple Sclerosis Provides Clues for Environmental Triggers of the Disease.
Voltage-gated potassium channels in multiple sclerosis: Overview and new implications for treatment of central nervous system inflammation and degeneration.
Evaluation of pattern-reversal visual evoked potential in patients with neuromyelitis optica.
Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease.
Architecture of human mTOR complex 1.
Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.

Pages